NCT00679523已完成2 期
An Open-Label, Rising Multiple-Dose, Multi-Center Study to Evaluate the Safety and Efficacy of Topically Applied AN2690 5.0% and 7.5% Solution for the Treatment of Adult Subjects With Onychomycosis of the Great Toenail
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 60
- 试验地点
- 9
- 主要终点
- A calculated endpoint of treatment response at Day 180 comprised of the ISGA, clear nail growth and fungal culture results
研究概览
简要总结
The purpose of the study is to determine the safety and efficacy of 5.0% and 7.5% AN2690 Solution in the treatment of distal, subungual onychomycosis of the great target toenail.
详细描述
The first group of 30 protocol-qualified subjects will be assigned to Treatment Group 1 and given 5% AN2690 Solution. Provided that there is adequate evidence of clinical safety after two weeks of dosing with 5% AN2690 Solution, a second group of 30 protocol-qualified subjects will be assigned to Treatment Group 2 and given 7.5% AN2690 Solution. A third group of 30 subjects will be enrolled and assigned the highest safe concentration of AN2690 evaluated in this study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Witnessed, signed informed consent approved by Ethics Committee
- •Male or female subjects of any race at least 18 years of age but not older than 65 years of age at the time of screening
- •Subjects with a diagnosis of onychomycosis of at least one great toenail and with a positive KOH wet mount from that nail
- •Onychomycosis involving 20-60% of the affected great toenail as determined by visual inspection after the nail has been trimmed
- •The combined thickness of the distal nail plate and the associated hyperkeratotic nail bed <3 mm
- •Affected great toenail to be treated is capable of re-growth as documented by history or recent observation of at least 2 mm of growth
- •Normal or not clinically significant screening safety labs
排除标准
- •Females of childbearing potential not using a highly effective method of birth control (e.g. implants, injectables, combined oral contraceptives, some intrauterine contraceptive devices) during the study
- •Diabetes mellitus requiring treatment other than diet and exercise
- •Subjects with chronic moccasin type of T. pedis
- •Subjects with a history of having failed any previous topical antifungal therapy for their onychomycosis
- •Subjects unwilling to refrain from the use of nail cosmetics such as clear and or colored nail lacquers from the screening visit until the end of the study.
- •Subjects that have not undergone the specified washout period(s) for the following topical preparations or subjects who require the concurrent use of any of the following topical medications:
- •Topical antifungal applied to the feet (does not include antifungals for treatment of T. pedis during the study): 4 weeks
- •Anti-inflammatories, corticosteroids, topical immunomodulators: 2 weeks
- •Subjects that have not undergone the specified washout period(s) for the following systemic medications or subjects who require the concurrent use of any of the following systemic medications:
- •Corticosteroids (including intramuscular injections): 2 weeks
- •Antifungals for treatment of onychomycosis or any systemic antifungal with known activity against dermatophytes: 24 weeks
- •Systemic immunomodulators: 4 weeks
- •Treatment of any type for cancer within the last 6 months
- •History of any significant internal disease
- •Subjects with a medical history of current or past psoriasis of the skin and/or nails
- •Concurrent lichen planus
- •Subjects who are known to be allergic to any of the test product(s) or any components in the test product(s) or history of hypersensitivity or allergic reactions to any of the study preparations as described in the Investigator's Brochure
- •Nail or anatomic abnormalities of the toe, e.g., genetic nail disorders, primentary disorders, onychogryphosis, trauma to the nail(s) to be treated
- •AIDS or AIDS related complex
- •History of street drug or alcohol abuse
- •Any subject not able to meet the study attendance requirements
- •Subjects who have participated in any other trial of an investigational drug or device within 60 days prior to enrollment or participation in a research study concurrent with this study
研究组 & 干预措施
Group 1
Experimental
AN2690 Solution, 5.0%
干预措施: AN2690 Solution, 5.0% (Drug)
Group 2
Experimental
AN2690 Solution, 7.5%
干预措施: AN2690 Solution, 7.5% (Drug)
结局指标
主要结局
A calculated endpoint of treatment response at Day 180 comprised of the ISGA, clear nail growth and fungal culture results
时间窗: Day 180
次要结局
- Mycological and clinical response of "complete responders", "partial responders", and "non-responder".(Days 180)
研究者
研究点 (9)
Loading locations...
相似试验
已完成
2 期
Safety and Efficacy Study of Subjects With Onychomycosis of the Great ToenailOnychomycosisNCT01278394Pfizer29
招募中
1 期
A Study on the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of CAN106 in Subjects With PNHPNHHemolysisNCT05539248CARE Pharma Shanghai Ltd.78
已完成
2 期
PF-06741086 Multiple Dose Study in Severe HemophiliaHemophilia A or BNCT02974855Pfizer27
已完成
1 期
Study of TAK-733 in Adult Patients With Advanced Nonhematologic MalignanciesAdvanced Non-hematologic MalignanciesAdvanced Metastatic MelanomaNCT00948467Millennium Pharmaceuticals, Inc.51
招募中
1 期
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)Advanced Solid TumorMetastatic Solid TumorSoft Tissue Sarcoma (STS)Platinum-resistant Ovarian Cancer (PROC)Hepatocellular Carcinoma (HCC)Colorectal Cancer (CRC)HER2 Negative Breast CancerRenal Cell Carcinoma (RCC)Cutaneous MelanomaNCT05824975GI Innovation, Inc.358